Molecular Profiling for Clinical Decision Making in Advanced Cancer: A Clinical Appraisal

Jaume Capdevila¹, Federico Rojo², Antonio González-Martín³, Enrique Grande⁴, Salvador Martín-Algarra⁵, Javier Puente⁶, Begoña Soler López^7, , Ruth Vera⁵ and Jesús García-Foncillas⁸

¹Vall d'Hebron University Hospital, Vall Hebron Institute of Oncology (VHIO), Barcelona, Spain

²Pathology Department, Fundación Jiménez Díaz University Hospital, Madrid, Spain

³Anderson Cancer Center, Medical Oncology Department Madrid, Spain

⁴Hospital Universitario Ramón y Cajal, Medical Oncology Department, Madrid, Spain

⁵Medical Oncology Department, Clínica Universitaria de Navarra, Pamplona, Spain

⁶Medical Oncology Department, Hospital Clínico Universitario San Carlos, Thoracic, Urologic & Melanoma Cancer Unit, Madrid, Spain

⁷Medical Department, Las Rozas (Madrid), Spain

⁸Department of Oncology, University Hospital “Fundación Jiménez Díaz”, Autonomous University of Madrid, Madrid, Spain

Cite this paper:
Jaume Capdevila, Federico Rojo, Antonio González-Martín, Enrique Grande, Salvador Martín-Algarra, Javier Puente, Begoña Soler López, Ruth Vera and Jesús García-Foncillas. Molecular Profiling for Clinical Decision Making in Advanced Cancer: A Clinical Appraisal. Journal of Cancer Research and Treatment. 2017; 5(3):77-85. doi: 10.12691/jcrt-5-3-1

Abstract

In the past five years, technological advances in the field of precision medicine in oncology have led to the emergence of a number of commercially available services for tumor profiling. There is an increased acceptance of these services that can help in finding treatment options based on molecular alterations as individual case reports have shown outstanding response to targeted therapies. Tumor profiling must seek to augment, rather than replace, existing local testing with the objective of helping more patients to find appropriate treatment options. The opportunity has arrived to integrate these services into the clinical setting, specifically in cases of refractory and rare tumors. The promise of precision medicine is clear but conclusive demonstration of how each of the different services delivers on the promise is not uniformly forthcoming. The selection of which service is most appropriate must be based on demonstrated analytical validation, quality standards, and data on clinical benefit and utility. The aims of this paper are to evaluate three tumor tissue profiling services commercially available and to propose to the physician how molecular profiling information can be used in clinical treatment decisions today.

Keywords:
molecular profiling cancer precision medicine refractory tumors rare tumors

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Garraway LA, Verweij J, Ballman KV. Precision oncology: an overview. J Clin Oncol, 2013; 31: 1803-5.
[2]	Ruckdeschel JC, Finkelstein DM, Ettinger DS et al. A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer. Journal of Clinical Oncology, 1986; 4: 14-22.
[3]	Lu S, Yu Y, Chen Z et al. Maintenance Therapy Improves Survival Outcomes in Patients with Advanced Non-small Cell Lung Cancer: A Meta-analysis of 14 Studies. Lung, 2015; 193: 805-14.
[4]	Welch H, Schwartz LM, Woloshin S. Are increasing 5-year survival rates evidence of success against cancer? JAMA, 2000; 283: 2975-8.
[5]	Le Tourneau C, Delord JP, Gonclaves A et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol, 2015; 16:1324-34.
[6]	Miller RC. Problems in rare tumor study: a call for papers. Rare tumors, 2010; 2: e16.
[7]	Conti RM, Bernstein AC, Villaflor VM et al. Prevalence of Off-Label Use and Spending in 2010 Among Patent-Protected Chemotherapies in a Population-Based Cohort of Medical Oncologists. Journal of Clinical Oncology, 2013; 31: 1134-9.
[8]	Olmos D, A'Hern RP, Marsoni S et al. Patient Selection for Oncology Phase I Trials: A Multi-Institutional Study of Prognostic Factors. Journal of Clinical Oncology, 2012; 30: 996-1004.
[9]	Planchat E, Abrial C, Thivat E et al. Late lines of treatment benefit survival in metastatic breast cancer in current practice?. Breast, 2011;20: 574-8.
[10]	Reinmuth N, Payer N, Muley T et al. Treatment and outcome of patients with metastatic NSCLC: a retrospective institution analysis of 493 patients. Respiratory Research, 2013; 14: 1-9.
[11]	River G, Moore S, Tucker J, Markman M. An Experience with Managing Cancer Patients Reportedly Previously Informed of the Absence of Additional Available Antineoplastic Therapeutic Options. Case Reports in Oncology, 2014; 7: 633-7.
[12]	NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol, 2008; 26:4617-25.
[13]	Caris Life Sciences profile information at: http://www.carismolecularintelligence.com/solid_tumors_international (accessed 05.02.2017).
[14]	Foundation medicine information at: http://foundationone.com/docs/FoundationOne_tech-info-and-overview.pdf (accessed 05.02.2017).
[15]	OncoDNA information at: http://www.oncodna.com/distributors/docs/products.pdf (accessed 05.02.2017).
[16]	Frampton GM, Fichtenholtz A, Otto GA et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotech, 2013; 31: 1023-31.
[17]	Weigelt B, Warne PH and Downward J. PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs. Oncogene, 2011; 30 (29): 3222-33.
[18]	Hortobagyi GN, Chen D, Piccart M et al. Correlative analysis of genetic alterations and everolimus benefit in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Results from BOLERO-2. J Clin Oncol, 2016; 34: 419-26.
[19]	André F, Hurvitz S, Fasolo A et al. Molecular alterations and everolimus efficacy in human epidermal growth factor receptor 2-overexpressing metastatic breast cancers: Combined exploratory biomarker analysis from BOLERO-1 and BOLERO-3. J Clin Oncol, 2016; 34: 2115-24.
[20]	Harris, T, Atkins D, Woolf SHet al. Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med, 2001; 20(3S): 21-35.
[21]	Raymaekers M, Cnops L, Vanmassenhove B et al. 2015 Five years of experience with ISO15189 accreditation in Belgian molecular diagnostics laboratories. Presented on behalf of MolecularDiagnostics.be and accessed at http://www.moleculardiagnostics.be/site/data/images/content/files/Van_Lint_EMMD15.pdf (accessed 05.02.2017).
[22]	ISO15189 accreditation for Institut de Patholgie et de Genetique Gosselies accessed at http://ng3.economie.fgov.be/NI/belac/medilabs/scope_pdf/381-MED.pdf (accessed 05.02.2017).
[23]	Holtzman NA, Watson MS. Promoting safe and effective genetic testing in the United States. Final report of the Task Force on Genetic testing, 1997. https://www.genome.gov/10001733/ (accessed 05.02.2017).
[24]	Ussia G, Leonard R, Janssens J. Multi-platform tumour profiling delivers the highest clinical utility and improves patient outcomes in today’s routine clinical practice. International Journal of Surgery & Surgical Procedures, 2016, 1: 107.
[25]	Von Hoff DD, Stephenson JJ, Rosen P, et al. Pilot study using molecular profiling of patients' tumours to find potential targets and select treatments for their refractory cancers. J Clin Oncol, 2010; 28: 4877-83.
[26]	Epelbaum R, Shacham-Shmueli E, Klein B et al. Molecular Profiling-Selected Therapy for Treatment of Advanced Pancreaticobiliary Cancer: A Retrospective Multicenter Study. BioMed Research International, 2015, Article ID 681653, 2015.
[27]	Jameson GS, Petricoin EF, Sachdev J et al. A Pilot Study Utilizing Multi-omic Molecular Profiling to find Potential Targets and Select Individualized Treatments for Patients with Previously Treated Metastatic Breast Cancer. Breast Cancer Res Treat, 2014 Oct;147:579-88.
[28]	Dean A, Byrne A, Marinova M, and Hayden I. Clinical outcomes of patients with rare and heavily pretreated solid tumors treated according to the results of tumor molecular profiling. BioMed Research International, 2016; Article ID 4627214.
[29]	Popovtzer A, Sarfaty M, Limon D et al. Metastatic Salivary Gland Tumours: A Single-center Study Demonstrating the Feasibility and Potential Clinical Benefit of Molecular-profiling-guided Therapy. BioMed Research International, 2015, Article ID 614845, 2015.
[30]	Purim O, Shacham-Shmueli E, Beny Aet al.. Molecular profiling-selected treatment in metastatic gastric and esophageal cancer: Real-life clinical experience. BioMed Research International (in press).
[31]	El Ahmadie A, Ibrahim T, El Karak F et al. Molecular profiling guided treatment in refractory solid tumours: practical impact and clinical responses: Experience of a single center. European Journal of Cancer, 2015; 51: S43.
[32]	Seeber A, Gastl G, Ensinger C, et al. Treatment of patients with refractory metastatic cancer according to a molecular profiling on tumor tissue: an interim-analysis of the ONCO-T-PROFILE Project. Genes Cancer, 2016; 7: 301-8. Chahine G, Nasr F, Saleh K et al. Clinical outcomes of patients with previously untreated advanced or metastatic cancer before or after tumour profiling: results of a monocentric pilot study in Lebanon. Presented at ICACT 2016.
[33]	Spetzler D, Xiao N, Burnett K et al. Multi-platform molecular profiling of 1,180 patients increase median overall survival and influences treatment decision in 53% of cases. Presented at ECCO 2015.
[34]	Herzog TJ, Spetzler D, Xiao N et al. Impact of molecular profiling on overall survival of patients with advanced ovarian cancer. Oncotarget, 2016;7:19840-9.
[35]	Marshall J, Schwartzberg LS, Bepler G et al. Novel panomic validation of time to next treatment (TNT) as an effective surrogate outcome measure in 4,729 patients. J Clin Oncol 34, 2016 (suppl; abstr 11521).
[36]	Braiteh F, Sharman J, Richards D et al. Clinical NGS-based cancer genomic profiling impacts physician treatment decisions in advanced solid tumours. J Clin Oncol, 2014; 32:5s(suppl; abstr 11109).
[37]	Ganesan P, Moulder S, Lee JJ et al. Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: Improved outcomes with combination chemotherapy and targeted agents. Mol Cancer Ther, 2014; 13: 3175-84.
[38]	Ferreira AR, Gomes ASDA, Hoff PM et al. Next generation sequencing – A key in search of locks? Ann Oncol, 2014; 25 (suppl 4): iv560.
[39]	Wheler JJ, Janku F, Naing A et al. Cancer therapy directed by comprehensive genomic profiling: A single center study. Cancer Res, 2016; 76:3690-701.
[40]	Parker BA, Schwaederle MC, Schwab RB et al. Precision oncology: the UC San Diego Moores Cancer Center PREDICT experience. J Clin Oncol 33, 2015 (suppl; abstr 11103).
[41]	Sohal D, Rini BI, Khorana AA et al. Prospective clinical study of precision oncology in solid tumours. J Clin Oncol 33, 2015 (suppl; abstr 6585).
[42]	David KA and Juhl H. Immunohistochemical Detection of Phosphoproteins and Cancer Pathways. Handbook of Practical Immunohistochemistry, 2015 Chapter 8, pages 85-90.
[43]	Swanton C, Soria J-C, Bardelli A et al. Consensus on precision medicine for metastatic cancers: a report from the MAP conference. Annals of Oncology, 2016; 27: 1443-8.